A Phase I Study of Buparlisib (BKM120) and Ofatumumab or Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Buparlisib (Primary) ; Ibrutinib; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 15 Sep 2016 Planned End Date changed from 1 Jan 2023 to 1 Sep 2017.
- 15 Sep 2016 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2017.
- 15 Sep 2016 Status changed from recruiting to active, no longer recruiting.